SEC Form 4 · accession 0001213900-26-098970
RELMADA THERAPEUTICS, INC. · RLMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maged Shenouda
Officer — Chief Financial Officer
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 7:30 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001553643
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 9, 2026 | P | 120,200 | $4.20 | A | 920,200 | D | |
| Common Stock | Sep 10, 2026 | P | 79,800 | $4.25 | A | 1,000,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- F2Purchase prices range from $4.16 to $4.20 per share, inclusive.